Sphera Funds Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sphera Funds Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7,000	Closed	-$1.93M	–	111
2024 Q3	$1.93M	Buy	+7,000	New	+$1.82M	0.31%	86
2024 Q1	–	Sell	-36,230	Closed	-$6.04M	–	105
2023 Q4	$6.93M	Buy	36,230 +129	+0.4%	+$22K	1.12%	33
2023 Q3	$6.39M	Sell	36,101 -3,899	-10%	-$744K	1.16%	29
2023 Q2	$7.6M	Buy	+40,000	New	+$7.93M	1.19%	24
2022 Q2	–	Sell	-24,768	Closed	-$3.51M	–	59
2022 Q1	$4.04M	Buy	+24,768	New	+$3.77M	0.57%	42
2018 Q4	–	Sell	-40,000	Closed	-$3.5M	–	103
2018 Q3	$3.5M	Sell	40,000 -155,232	-80%	-$15.6M	0.4%	74
2018 Q2	$19.2M	Buy	+195,232	New	+$19.4M	2.65%	9
2017 Q3	–	Sell	-50,000	Closed	-$3.99M	–	132
2017 Q2	$3.99M	Buy	+50,000	New	+$3.2M	0.68%	46
2016 Q2	–	Sell	-70,000	Closed	-$4.41M	–	95
2016 Q1	$4.39M	Buy	70,000 +30,000	+75%	+$1.99M	0.95%	16
2015 Q4	$3.77M	Hold	40,000	–	–	0.55%	33
2015 Q3	$3.21M	Buy	40,000 +3,000	+8%	+$333K	0.41%	51
2015 Q2	$4.43M	Buy	+37,000	New	+$4.42M	0.43%	51

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Sphera Funds Management's ALNY Position: Q4 2024 in Review

Sphera Funds Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 7,000 shares — an estimated $1.93M sold.

Sphera Funds Management first reported a position in ALNY in Q2 2015 and held it in 12 quarters. The position peaked at $19.2M in Q2 2018. 594 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

Sphera Funds Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Sphera Funds Management sold 7,000 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $1.93M.
Sphera Funds Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 12 quarters.
Sphera Funds Management's Alnylam Pharmaceuticals position peaked at $19.2M in Q2 2018.
594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Sphera Funds Management's 13F filing for Q4 2024, filed 14 Feb 2025.